1086 related articles for article (PubMed ID: 21913440)
1. [Complications of intravitreal injections--own experience].
Jamrozy-Witkowska A; Kowalska K; Jankowska-Lech I; Terelak-Borys B; Nowosielska A; Grabska-Liberek I
Klin Oczna; 2011; 113(4-6):127-31. PubMed ID: 21913440
[TBL] [Abstract][Full Text] [Related]
2. [Intravitreal triamcinolone acetonide for the treatment of intraocular edematous and neovascular diseases].
Jonas JB; Kreissig I; Kamppeter B; Degenring RF
Ophthalmologe; 2004 Feb; 101(2):113-20. PubMed ID: 14991306
[TBL] [Abstract][Full Text] [Related]
3. Incidence of endophthalmitis and use of antibiotic prophylaxis after intravitreal injections.
Cheung CS; Wong AW; Lui A; Kertes PJ; Devenyi RG; Lam WC
Ophthalmology; 2012 Aug; 119(8):1609-14. PubMed ID: 22480743
[TBL] [Abstract][Full Text] [Related]
4. Intravitreal triamcinolone acetonide for treatment of intraocular oedematous and neovascular diseases.
Jonas JB
Acta Ophthalmol Scand; 2005 Dec; 83(6):645-63. PubMed ID: 16396641
[TBL] [Abstract][Full Text] [Related]
5. Bilateral simultaneous intravitreal injections in the office setting.
Bakri SJ; Risco M; Edwards AO; Pulido JS
Am J Ophthalmol; 2009 Jul; 148(1):66-9.e1. PubMed ID: 19403114
[TBL] [Abstract][Full Text] [Related]
6. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES).
Wu L; Martínez-Castellanos MA; Quiroz-Mercado H; Arevalo JF; Berrocal MH; Farah ME; Maia M; Roca JA; Rodriguez FJ;
Graefes Arch Clin Exp Ophthalmol; 2008 Jan; 246(1):81-7. PubMed ID: 17674014
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal triamcinolone acetonide: a change in a paradigm.
Jonas JB
Ophthalmic Res; 2006; 38(4):218-45. PubMed ID: 16763379
[TBL] [Abstract][Full Text] [Related]
8. [Intravitreous injection: retrospective study on 2028 injections and their side effects].
Angulo Bocco MC; Glacet-Bernard A; Zourdani A; Coscas G; Soubrane G
J Fr Ophtalmol; 2008 Sep; 31(7):693-8. PubMed ID: 18971854
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal triamcinolone acetonide vs bevacizumab for treatment of macular oedema secondary to branch retinal vein occlusion.
Cheng KC; Wu WC; Chen KJ
Eye (Lond); 2009 Nov; 23(11):2023-33. PubMed ID: 19798117
[TBL] [Abstract][Full Text] [Related]
10. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
Ding X; Li J; Hu X; Yu S; Pan J; Tang S
Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
[TBL] [Abstract][Full Text] [Related]
11. Ocular morbidity associated with intravitreal triamcinolone acetonide.
Konstantopoulos A; Williams CP; Newsom RS; Luff AJ
Eye (Lond); 2007 Mar; 21(3):317-20. PubMed ID: 16710433
[TBL] [Abstract][Full Text] [Related]
12. Cataract surgery combined with intravitreal injection of triamcinolone acetonide.
Jonas JB; Kreissig I; Budde WM; Degenring RF
Eur J Ophthalmol; 2005; 15(3):329-35. PubMed ID: 15945000
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration].
Bidot ML; Malvitte L; Bidot S; Bron A; Creuzot-Garcher C
J Fr Ophtalmol; 2011 Jun; 34(6):376-81. PubMed ID: 21550687
[TBL] [Abstract][Full Text] [Related]
14. Intravitreal triamcinolone acetonide vs bevacizumab for treatment of macular oedema due to central retinal vein occlusion.
Wu WC; Cheng KC; Wu HJ
Eye (Lond); 2009 Dec; 23(12):2215-22. PubMed ID: 19218991
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal triamcinolone acetonide injection for macular edema due to central retinal vein occlusion persisting despite multiple intravitreal bevacizumab injections.
Alshareef RA; Garg SJ; Hsu J; Vander J; Park C; Spirn MJ
J Ocul Pharmacol Ther; 2014 Aug; 30(6):512-6. PubMed ID: 24828198
[TBL] [Abstract][Full Text] [Related]
16. A comparison of three different intravitreal treatment modalities of macular edema due to branch retinal vein occlusion.
Cekiç O; Cakır M; Yazıcı AT; Alagöz N; Bozkurt E; Faruk Yılmaz O
Curr Eye Res; 2010 Oct; 35(10):925-9. PubMed ID: 20858114
[TBL] [Abstract][Full Text] [Related]
17. [Treatment of oedematous, proliferative and neovascular diseases by intravitreal triamcinolone acetonide].
Jonas JB; Kreissig I; Degenring RF
Klin Monbl Augenheilkd; 2003 Jun; 220(6):384-90. PubMed ID: 12830391
[TBL] [Abstract][Full Text] [Related]
18. Sterile endophthalmitis after intravitreal triamcinolone: a possible association with uveitis.
Taban M; Singh RP; Chung JY; Lowder CY; Perez VL; Kaiser PK
Am J Ophthalmol; 2007 Jul; 144(1):50-54. PubMed ID: 17601427
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal triamcinolone acetonide compared with bevacizumab for the treatment of patients with macular edema secondary to central retinal vein occlusion.
Gokce G; Sobaci G; Durukan AH; Erdurman FC
Postgrad Med; 2013 Sep; 125(5):51-8. PubMed ID: 24113663
[TBL] [Abstract][Full Text] [Related]
20. Comparing intravitreal triamcinolone acetonide and bevacizumab injections for the treatment of diabetic macular oedema: a randomized double-blind study.
Isaac DL; Abud MB; Frantz KA; Rassi AR; Avila M
Acta Ophthalmol; 2012 Feb; 90(1):56-60. PubMed ID: 20015098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
